PubMed Journals Articles About "Anthera Halts VISTA Heart Drug Trial" RSS

06:34 EDT 31st August 2014 | BioPortfolio

Anthera Halts VISTA Heart Drug Trial PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Anthera Halts VISTA Heart Drug Trial articles that have been published worldwide.

More Information about "Anthera Halts VISTA Heart Drug Trial" on BioPortfolio

We have published hundreds of Anthera Halts VISTA Heart Drug Trial news stories on BioPortfolio along with dozens of Anthera Halts VISTA Heart Drug Trial Clinical Trials and PubMed Articles about Anthera Halts VISTA Heart Drug Trial for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Anthera Halts VISTA Heart Drug Trial Companies in our database. You can also find out about relevant Anthera Halts VISTA Heart Drug Trial Drugs and Medications on this site too.

Showing "Anthera halts VISTA heart drug trial" PubMed Articles 1–25 of 16,000+

Extremely Relevant

Acute coronary syndromes: Targeting inflammation-what has the VISTA-16 trial taught us?

GenomeVISTA - an integrated software package for whole-genome alignment and visualization.

With the ubiquitous generation of complete genome assemblies for a variety of species, efficient tools for whole-genome alignment along with user-friendly visualization are critically important. Our VISTA family of tools for comparative genomics, based on algorithms for pairwise and multiple alignments of genomic sequences and whole-genome assemblies have become one of the standard techniques for comparative analysis. Most of the VISTA programs have been implemented as Web-accessible servers and are extensi...


An evaluation of the pharmacokinetics and pharmacodynamics of ivabradine for the treatment of heart failure.

Introduction: Ivabradine is a new heart-rate-lowering drug; the aim of this review was to analyze its role in heart failure (HF). Areas covered: This systematic review on the role of ivabradine in HF is based on material searched and obtained through Pubmed and Medline up to September 2013. Expert opinion: Heart rate (HR) is a risk factor in patients with HF, and its reduction is considered an important goal of therapy. The BEAUTIFUL trial demonstrated the benefits of ivabradine on prognosis (only on ischem...

42 Meta-Analysis Identifying the Source of Conflict Between Different Trial Reports on the Effect of CRT in Heart Failure with Narrow QRS Complexes.

Biventricular pacing (CRT) shows clear benefits in heart failure with wide QRS, but results in patients with narrow QRS have been conflicting. In this meta-analysis we tested the hypothesis that trial design might have influenced findings.

Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve).

Higher heart rate is associated with poorer outcomes in patients with heart failure and reduced ejection fraction (HF-REF). Less is known about the association between heart rate and outcomes in patients with heart failure and preserved ejection fraction (HF-PEF). Therefore, we examined the relationship between heart rate and outcomes in the irbesartan in patients with heart failure and preserved systolic function trial (I-Preserve) in patients with an ejection fraction >45% aged >60 years.

International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial.

The implications of geographical variation are unknown following adjustment for hospital length of stay (LOS) in heart failure (HF) trials that included patients whether or not they had systolic dysfunction. We investigated regional differences in an international acute HF trial.

Pharmacokinetics of Lacosamide and Omeprazole Coadministration in Healthy Volunteers: Results from a Phase I, Randomized, Crossover Trial.

The antiepileptic drug lacosamide has a low potential for drug-drug interactions, but is a substrate and moderate inhibitor of the cytochrome P450 (CYP) enzyme CYP2C19.

Chinese medicine shensongyangxin is effective for patients with bradycardia: results of a randomized, double-blind, placebo-controlled multicenter trial.

To evaluate the efficacy and safety of Shensong Yangxin (SSYX) in patients with bradycardia arrhythmias, a randomized, double-blind, and placebo-controlled study was conducted. Patients with bradycardia were randomly assigned to receive either SSYX (trial group, n = 115) or placebo (control group, n = 104) for 4 weeks. ECG, 24-hour continuous ECG recording, echocardiography, and hepatic and renal function were evaluated at baseline and after treatment. Results showed that the average heart rate, the fastest...

Adverse effects of benfluorex on heart valves and pulmonary circulation.

Benfluorex is responsible for the development of restrictive valvular regurgitation due to one of its metabolites, norfenfluramine. The 5-HT2B receptor, expressed on heart valves, acts as culprit receptor for drug-induced valvular heart disease (VHD). Stimulation of this receptor leads to the upregulation of target genes involved in the proliferation and stimulation of valvular interstitial cells through different intracellular pathways. Valve lesions essentially involve the mitral and/or aortic valves. The...

Statistical consideration and challenges in bridging study of personalized medicine.

Abstract Applications of personalized medicine are becoming increasingly prominent. A well-characterized market-ready companion diagnostic assay (CDx) is often desired for patient enrollment in device-drug pivotal clinical trial(s) so that Food and Drug Administration can ensure that appropriate clinical and analytical validation studies are planned and carried out for CDx. However, such a requirement may be difficult or impractical to accomplish. A clinical trial assay (CTA) instead of CDx may be used for...

Drug Use Trajectories After a Randomized Controlled Trial of MTFC: Associations with Partner Drug Use.

Trajectories of drug use were examined in a sample of women with prior juvenile-justice system involvement. One hundred fifty-three young women who participated in a randomized controlled trial of Multidimensional Treatment Foster Care (MTFC) in adolescence were assessed on five occasions over a 24-month period in young adulthood (mean age = 22.29 years at T1). Participants assigned to the MTFC condition during adolescence reported greater decreases in drug use than girls assigned to the treatment as usual...

Zebrafish heart failure models for the evaluation of chemical probes and drugs.

Abstract Heart failure is a complex disease that involves genetic, environmental, and physiological factors. As a result, current medication and treatment for heart failure produces limited efficacy, and better medication is in demand. Although mammalian models exist, simple and low-cost models will be more beneficial for drug discovery and mechanistic studies of heart failure. We previously reported that aristolochic acid (AA) caused cardiac defects in zebrafish embryos that resemble heart failure. Here, w...

Severe Decrease of Cyclosporine Levels in a Heart Transplant Recipient Receiving the Direct Thrombin Inhibitor Argatroban.

: This case report is about a suspected interaction between argatroban, a direct thrombin inhibitor, and cyclosporine, which occurred in a 60-year-old patient after a second heart transplantation. We explored 4 possible mechanisms of interaction, which are an analytical interference, an idiopathic hemodilution, an increase of renal and hepatic clearance, and a metabolic drug-drug interaction.

Risk-benefit assessment of ivabradine in the treatment of chronic heart failure.

Heart rate is not only a major risk marker in heart failure but also a general risk marker. Within the last few years, it has been demonstrated that reduction of resting heart rate to

Randomized Trial Comparing Robotic to Manual Ablation for Atrial Fibrillation.

Catheter ablation of atrial fibrillation (AF) is a physically demanding procedure for the operator, involving radiation exposure, and has limited success rates. Remote robotic navigation (RRN) may offer benefit to the procedure, though only one previous small randomized trial has assessed this.

Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT.

Hospitalization for worsening heart failure (HF) is known to increase mortality and morbidity risk and has been frequently used as an endpoint in randomized clinical trials. Whether outpatient management of HF exacerbation carries similar prognostic and therapeutic information is less well known, but could be important for the design of trials that use HF hospitalization as an endpoint.

Drug Development for Pediatric Neurogenic Bladder Dysfunction: Dosing, Endpoints, and Study Design.

Pediatric drug development is challenging when a product is studied for a pediatric disease that has a different underlying etiology and pathophysiology compared to the adult disease. Neurogenic bladder dysfunction (NBD) is such a therapeutic area with multiple unsuccessful development programs. The objective of this study was to critically evaluate clinical trial design elements that may have contributed to unsuccessful drug development programs for pediatric NBD. Trial design elements of drugs tested for...

A Randomised Controlled Trial of Catheter Ablation versus Medical Treatment of Atrial Fibrillation in Heart Failure (THE CAMTAF TRIAL).

-Restoring sinus rhythm in patients with heart failure (HF) and atrial fibrillation (AF) may improve left ventricular (LV) function and HF symptoms. We sought to compare the impact of a catheter ablation strategy with that of a medical rate control strategy in patients with persistent AF and HF.

A pilot study of target weight guided treatment in acute heart failure using ultrafiltration or usual care: effect on sodium removal.

In the Ultrafiltration versus Intravenous Diuretics for Patients Hospitalized for Acute Decompensated Heart Failure trial, ultrafiltration (UF) removed volume more effectively than usual care (UC). Hypothetically, UF may be superior to UC due to increased sodium (Na) removal and less neurohormonal activation. We compared UF and UC in a randomized pilot trial of target weight guided therapy for acute decompensated heart failure (ADHF).

Healthcare transition for youth with heart disease: a clinical trial.

Adolescents with heart disease have complex health needs and require lifelong cardiology follow-up. Interventions to facilitate paediatric to adult healthcare transition are recommended, although outcomes are unknown. We sought to determine the impact of a transition intervention on improving knowledge and self-management skills among this population.

FDA halts then allows sales of Ariad's leukemia medication.

Metformin in Diabetic Patients with Heart Failure: Safe and Effective?

Management of diabetic patients with heart failure is a complex endeavor. The initial reluctance to use metformin in these patients has given way to a broader acceptance after clinical trials and meta-analyses have revealed that some of the insulin-sensitizing agents lead to adverse cardiovascular events. We have proposed that an increase of substrate uptake by the insulin-resistant heart is detrimental because the heart is already flooded with fuel. In light of this evidence, metformin offers a unique safe...

Ageing is a risk factor in imatinib mesylate cardiotoxicity.

Chemotherapy-induced heart failure is increasingly recognized as a major clinical challenge. Cardiotoxicity of imatinib mesylate, a highly selective and effective anticancer drug belonging to the new class of tyrosine kinase inhibitors, is being reported in patients, some progressing to congestive heart failure. This represents an unanticipated challenge that could limit effective drug use. Understanding the mechanisms and risk factors of imatinib mesylate cardiotoxicity is crucial for prevention of cardiov...

Totally Percutaneous Endovascular Abdominal Aortic Aneurysm Repair: 30-Day Results from the Independent Access-Site Closure Study of the PEVAR Trial.

Clinical Trial Design in Contemporary Device Studies in Heart Failure: Is There A Gold Standard?

The assessment of the efficacy and safety of implantable cardiac devices used for the management of heart failure is complicated by procedural challenges. We present an overview of the advantages and disadvantages of different clinical trial designs, and discuss investigator and patient blinding. We conclude that blinding is optimal, but methodologically difficult. Until rules for and assessment of blinding are developed or surrogate measures are considered acceptable from a regulatory standpoint, an open l...

Search BioPortfolio:

PubMed Database Quicklinks